Cardioplegia is intentional and temporary cessation of cardiac activity, primarily for cardiac surgery.
The word cardioplegia combines the Greek cardio meaning the "heart", and plegia "paralysis". Technically, this means arresting or stopping the heart so that surgical procedures can be done in a still and bloodless field. Most commonly, however, the word cardioplegia refers to the solution used to bring about asystole of the heart, or heart paralysis.
The main goals of hypothermic cardioplegia are:
- Immediate and sustained electromechanical quiescence
- Rapid and sustained homogeneous myocardial cooling
- Maintenance of therapeutic additives in effective concentrations
- Periodic washout of metabolic inhibitors
The most common procedure for accomplishing asystole is infusing cold cardioplegic solution into the coronary circulation. This process protects the myocardium, or heart muscle, from damage during the period of ischemia.
To achieve this, the patient is first placed on cardiopulmonary bypass. This device, otherwise known as the heart-lung machine, takes over the functions of gas exchange by the lung and blood circulation by the heart. Subsequently, the heart is isolated from the rest of the blood circulation by means of an occlusive cross-clamp placed on the ascending aorta proximal to the innominate artery. During this period of heart isolation, the heart is not receiving any blood flow, thus no oxygen for metabolism. As the cardioplegia solution distributes to the entire myocardium, the ECG will change and eventually asystole will ensue. Cardioplegia lowers the metabolic rate of the heart muscle, thereby preventing cell death during the ischemic period of time.
Cardioplegic solution is the means by which the ischemic myocardium is protected from cell death. This is achieved by reducing myocardial metabolism through a reduction in cardiac work load and by the use of hypothermia.
Chemically, the high potassium concentration present in most cardioplegic solutions decreases the membrane resting potential of cardiac cells. The normal resting potential of ventricular myocytes is about -90 mV. When extracellular cardioplegia displaces blood surrounding myocytes, the membrane voltage becomes less negative and the cell depolarizes more readily. The depolarization causes contraction, intracellular calcium is sequestered by the sarcoplasmic reticulum via ATP-dependent Ca2+ pumps, and the cell relaxes (diastole). However, the high potassium concentration of the cardioplegia extracellular prevents repolarization. The resting potential on ventricular myocardium is about −84 mV at an extracellular K+ concentration of 5.4 mmol/l. Raising the K+ concentration to 16.2 mmol/l raises the resting potential to −60 mV, a level at which muscle fibers are inexcitable to ordinary stimuli. When the resting potential approaches −50 mV, sodium channels are inactivated, resulting in a diastolic arrest of cardiac activity. Membrane inactivation gates, or h Na+ gates, are voltage dependent. The less negative the membrane voltage, the more h gates that tend to close. If partial depolarization is produced by a gradual process such as elevating the level of extracellular K+, then the gates have ample time to close and thereby inactivate some of the Na+ channels. When the cell is partially depolarized, many of the Na+ channels are already inactivated, and only a fraction of these channels is available to conduct the inward Na+ current during phase 0 depolarization.
The use of two other cations, Na+ and Ca2+, also can be used to arrest the heart. By removing extracellular Na+ from perfusate, the heart will not beat because the action potential is dependent upon extracellular Na+ ions. However, the removal of Na+ does not alter the resting membrane potential of the cell. Likewise, removal of extracellular Ca2+ results in a decreased contractile force, and eventual arrest in diastole. An example of a low [K+] low [Na+] solution is histidine-tryptophan-ketoglutarate. Conversely, increasing extracellular Ca2+ concentration enhances contractile force. Elevating Ca2+ concentration to a high enough level results in cardiac arrest in systole. This unfortunate irreversible event is referred to as "stone-heart" or rigor.
Hypothermia is the other key component of most cardioplegic strategies. It is employed as another means to further lower myocardial metabolism during periods of ischemia. The Van 't Hoff equation allows calculation that oxygen consumption will drop by 50% for every 10°C reduction in temperature. This Q10 effect combined with a chemical cardiac arrest can reduce myocardial oxygen consumption (MV02) by 97%.
Cold cardioplegia is given into the heart through the aortic root. Blood supply to the heart arises from the aortic root through coronary arteries. Cardioplegia in diastole ensures that the heart does not use up the valuable energy stores (adenosine triphosphate). Blood is commonly added to this solution in varying amounts from 0 to 100%. Blood acts a buffer and also supplies nutrients to the heart during ischemia.
Once the procedure on the heart vessels (coronary artery bypass grafting) or inside the heart such as valve replacement or correction of congenital heart defect, etc. is over, the cross-clamp is removed and the isolation of the heart is terminated, so normal blood supply to the heart is restored and the heart starts beating again.
The cold fluid (usually at 4°C) ensures that the heart cools down to a temperature of around 15–20°C, thus slowing down the metabolism of the heart and thereby preventing damage to the heart muscle. This is further augmented by the cardioplegia component which is high in potassium.
When solution is introduced into the aortic root (with an aortic cross-clamp on the distal aorta to limit systemic circulation), this is called antegrade cardioplegia. When introduced into the coronary sinus, it is called retrograde cardioplegia.
- Cardiopulmonary bypass
- Deep hypothermic circulatory arrest
- B05XA16 (WHO)
- Cardioplegia at the US National Library of Medicine Medical Subject Headings (MeSH)
- Resting potential
- Action potential
- Membrane potential
- Kaplan J Cardiac Anesthesia. 3rd Edition. W.B Saunders Company. 1993
- "Cold Crystalloid Cardioplegia" Hans J. Geissler* and Uwe Mehlhorn, Department of Cardiothoracic Surgery, University of Cologne
- Aaron. "CV Physiology: Membrane Potentials". Retrieved 8 November 2016.
- Hensley F, Martin D. A Practical Approach to Cardiac Anesthesia. 2nd Edition. Little, Brown and Company. 1995
- Berne R, Levy M. Physiology. 3rd Edition. Mosby St. Louis 1993.
- Gravlee G, Davis R, Utley J. Cardiopulonary Bypass Principles and Practice. Williams & Williams Baltimore 1993.
- "Cardioplegia Delivery Systems" Archived September 4, 2006, at the Wayback Machine. hosted on Washington University, St. Louis, web site